ImmunoGen announces $200M common stock offering

ImmunoGen announced that it intends to offer and sell, subject to market and other conditions, $200M of shares of its common stock in an underwritten public offering. ImmunoGen intends to use the net proceeds from this offering to fund its operations, including, but not limited to, global commercialization activities, supply of ELAHERE drug product, clinical trial activities, pipeline research and development activities, business development activities, and capital expenditures. Jefferies, Goldman Sachs & Co., and Guggenheim Securities are acting as joint book-running managers for the proposed offering.